SARS-CoV-2 Omicron variant spike protein — Drug Target

All drugs that target SARS-CoV-2 Omicron variant spike protein — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Viral vector vaccine

Phase 3 pipeline (1)

• AdCLD-CoV19-1 OMI · Cellid Co., Ltd. · Viral vector vaccine · Immunology / Infectious Disease
  AdCLD-CoV19-1 OMI is an adenoviral vector-based vaccine designed to elicit immune responses against Omicron variant SARS-CoV-2 antigens.